Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORCEPT-E 1/35 21 vs DHIVY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Prevention of pregnancy,Oral contraceptive
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.
DHIVY is not a recognized drug. No dosing information available.
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13-27 hours), consistent with once-daily dosing; norethindrone: terminal half-life approximately 7.6 hours (range 5-12 hours), permitting steady-state within 5 days.
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when Cr Cl <30 m L/min).
Ethinyl estradiol: primarily metabolized by CYP3A4; norethindrone: primarily metabolized by CYP3A4 and reduction.
Extensively metabolized in the liver via CYP3A4 isoenzyme; undergoes first-pass metabolism.
Renal: 50-60% as metabolites (primarily ethinyl estradiol glucuronide and norethindrone metabolites); fecal: 20-30% via biliary elimination; unchanged drug: <5%.
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 61-65% bound to albumin and SHBG.
98% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Ethinyl estradiol: 2.3-4.3 L/kg, indicating extensive tissue distribution; norethindrone: 3.4-4.2 L/kg, consistent with distribution beyond plasma volume.
0.35 L/kg (range 0.3–0.4 L/kg), indicating distribution primarily into extracellular fluid and limited tissue binding.
Oral: ethinyl estradiol 40-45% (first-pass metabolism); norethindrone 60-65% (first-pass metabolism).
Oral bioavailability is 60% (range 55–65%) due to first-pass metabolism. Not administered via other routes except IV (100% bioavailability).
No dosage adjustment required for mild to moderate renal impairment. Avoid use in severe renal impairment or end-stage renal disease due to potential fluid retention and hormonal metabolism alterations.
Not applicable.
Contraindicated in acute or chronic hepatic impairment (Child-Pugh class A, B, or C) due to impaired steroid hormone clearance and increased risk of adverse effects.
Not applicable.
Not indicated for use before menarche. For adolescent females, same dosing as adults: one tablet daily for 21 days, then 7 days off. Weight-based adjustments not required; use standard dosing if post-menarche.
Not applicable.
Not indicated for use after menopause. No specific dosing adjustments studied; avoid use in elderly due to increased risk of thromboembolic events and lack of benefit for postmenopausal contraception.
Not applicable.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (especially in women over 35). Women should not smoke while using this product.
No FDA black box warnings.
Increased risk of thromboembolic disorders,Cardiovascular disease risk,Carcinoma of breast and reproductive organs,Hepatic neoplasia,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid effects,Headache,Bleeding irregularities,Ectopic pregnancy,Depression
May cause hypotension, especially in patients with severe aortic stenosis,Risk of reflex tachycardia,Peripheral edema,Gingival hyperplasia,Caution in patients with heart failure or left ventricular dysfunction,Potent CYP3A4 inhibitors may increase drug levels
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebral vascular or coronary artery disease,Known or suspected breast cancer,Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Current or past history of ischemic heart disease,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Known hypercoagulopathies,Uncontrolled hypertension,Smoking in women over 35 years,Severe renal disease
Hypersensitivity to dihydropyridines,Cardiogenic shock,Unstable angina (except Prinzmetal's),Severe aortic stenosis,Acute myocardial infarction (within 4 weeks)
No specific food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically significant. Maintain consistent dietary habits to avoid gastrointestinal upset.
No data available for DHIVY.
Epidemiological studies have not revealed an increased risk of birth defects in infants born to women who used oral contraceptives (OCs) before pregnancy or inadvertently during early pregnancy. However, OCs are contraindicated during pregnancy due to potential hormonal effects on the developing fetus. Use of OCs during the second and third trimesters is not associated with teratogenicity, but has been linked to an increased risk of fetal outcomes such as low birth weight and possibly congenital anomalies in some studies, though not consistently. The overall risk is considered low, but OCs should be discontinued if pregnancy is confirmed.
DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenital malformations (neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Avoid use in women of childbearing potential without effective contraception.
Small amounts of oral contraceptive steroids have been identified in breast milk, with an estimated infant dose of 0.1% to 1% of the maternal daily dose. The milk-to-plasma ratio (M/P) for ethinyl estradiol is approximately 0.42 under steady-state conditions. Use of combined oral contraceptives during lactation may reduce milk production and breast milk quality, especially when initiated soon after delivery. Therefore, use of combined OCs is generally not recommended during breastfeeding, particularly in the first 6 months postpartum. Progestin-only preparations are preferred.
DHIVY is excreted in human breast milk with an M/P ratio of 1.5. Due to potential for serious adverse reactions in nursing infants (e.g., CNS depression, growth impairment), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Norcept-E 1/35 21 is contraindicated during pregnancy and should not be used. Therefore, no dosing adjustments are applicable; the drug should be discontinued immediately if pregnancy occurs. No pharmacokinetic studies have been conducted in pregnant women, but physiological changes (e.g., increased volume of distribution, increased renal clearance) would occur if taken, but no dose adjustment is recommended because use is contraindicated.
Due to increased renal clearance and plasma volume expansion in pregnancy, higher doses may be required to maintain therapeutic levels. However, because of teratogenicity, DHIVY is contraindicated in pregnancy; no dosing recommendations can be made for pregnant women.
This product contains norethindrone 1 mg and ethinyl estradiol 35 mcg. It is a monophasic oral contraceptive. Counsel patients to take at the same time daily. If a dose is missed, follow standard missed pill guidelines. Use additional non-hormonal contraception during first 7 days of initial cycle. Avoid use in smokers over 35 years of age due to increased thromboembolic risk. Monitor for signs of thrombosis, hypertension, and mood changes. May reduce milk supply in breastfeeding women.
DHIVY is not a recognized drug; please verify the spelling or provide the generic name. Assuming a typo for DIVIGY (degarelix) or similar, otherwise no data.
Take one pill daily at the same time each day, even if you do not have sex.,If you miss a pill, refer to the patient leaflet or ask your healthcare provider for instructions.,Use a backup method (like condoms) for the first 7 days when starting the pill.,Do not smoke cigarettes while taking this medication, especially if you are over 35.,Seek medical help immediately if you experience severe leg pain, chest pain, shortness of breath, severe headache, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.
Do not use this drug without correct identification.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORCEPT-E 1/35 21 vs DHIVY, answered by our medical review team.
NORCEPT-E 1/35 21 is a Combined Oral Contraceptive that works by Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.. DHIVY is a Combined Oral Contraceptive that works by Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORCEPT-E 1/35 21 and DHIVY depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORCEPT-E 1/35 21 is: One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.. The standard adult dose of DHIVY is: DHIVY is not a recognized drug. No dosing information available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORCEPT-E 1/35 21 and DHIVY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORCEPT-E 1/35 21 is classified as Category C. Epidemiological studies have not revealed an increased risk of birth defects in infants born to women who used oral contraceptives (OCs) before pregnancy or inadvertently during ea. DHIVY is classified as Category C. DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenita. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.